You are here

mirevtuximab soravtansine

FDA Action Alert: Spectrum, ImmunoGen, Scynexis and Y-mAbs

BioSpace

Mon, 11/21/22 - 10:06 am

Spectrum Pharmaceuticals

mirevtuximab soravtansine

FDA tells ImmunoGen to run a second phase 3, sinking stock

Fierce Biotech

Wed, 05/15/19 - 10:38 am

mirevtuximab soravtansine

clinical trials

6 Key Cancer Winners From ASCO Presentations

24/7 Wall St

Mon, 06/1/15 - 10:06 am

mirevtuximab soravtansine

Vascular Biogenics

sacituzumab govitecan